First Tracks Biotherapeutics Inc's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Shows the company secured its headquarters facility for one year with extension options, affecting operating costs.
Allows early investors to sell their shares publicly, indicating the company went public on April 20, 2026.
Company became independent from AnaptysBio on April 20, 2026, with shares now trading on Nasdaq under TRAX.
First required quarterly filing shows the company's financial performance after becoming independent.
Shares earnings performance with investors shortly after the company's April 20 spin-off from AnaptysBio.
Formally registers First Tracks as a public company separate from parent AnaptysBio before April 20, 2026 spin-off.
First Tracks became a standalone public company on April 20, 2026, with AnaptysBio holding initial 29.1 million shares.
Stocky reads First Tracks Biotherapeutics Inc's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
First Tracks Biotherapeutics Inc's most recent tracked filing was a 8-K on 22 Jun 2026: Sublease 45,057 square feet San Diego office space from AnaptysBio.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.